The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

November 01, 2018

Milind Javle, MD, discusses findings from a phase II study of infigratinib in patients with intrahepatic cholangiocarcinoma, emphasizing the importance of molecular testing.

October 16, 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

October 12, 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

October 11, 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.

October 10, 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses accelerated phase myelofibrosis.

October 09, 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

October 05, 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immunotherapy in prostate cancer.

October 04, 2018

James P. Allison, PhD, reflects on his research in immunology, the impact it has had on patients with cancer, and where the field is headed.

October 02, 2018

James P. Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the future of immunotherapy in the treatment of patients with cancer.

September 29, 2018

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of PARP inhibitors in patients with ovarian cancer.

September 27, 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

September 26, 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses quizartinib for the treatment of patients with acute myeloid leukemia.

September 25, 2018

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.

September 19, 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

September 18, 2018

Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.

September 10, 2018

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses impactful targeted therapies in lung cancer.

September 10, 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.

September 10, 2018

Padmanee Sharma, MD, PhD, shares her insight on the current state of immunotherapy in the treatment of patients with genitourinary cancers.

September 07, 2018

Scott Kopetz, MD, PhD, FACP, discusses the current treatment landscape of colorectal cancer and the importance of molecular subtyping.

September 06, 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses regional nodal irradiation for the treatment of patients with breast cancer.